Navigation Links
Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
Date:8/27/2009

PITTSBURGH, Aug. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The preparation is the first generic version of Sanofi Aventis' BenzaClin(R) to be approved by the U.S. Food and Drug Administration (FDA).

On Aug. 11, Dow received FDA approval for its Abbreviated New Drug Application (ANDA) for Clindamycin 1% and Benzoyl Peroxide 5% Gel, a prescription-strength topical antibiotic used to treat acne. According to IMS Health, BenzaClin had total U.S. sales of approximately $221 million for the 12 months ending June 30.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
2. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
3. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
4. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
5. Mylan Announces Enhancements to Executive Management Team
6. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
7. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
8. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
11. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... Jamaica (PRWEB) , ... April 30, 2016 , ... ... and Duane Boise, President and CEO of EMED, today signed a multifaceted agreement ... , EMED and the Northern Caribbean University Department of Natural and Applied Sciences, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... April 4th, 2016 questioned the use of the HyProCure sinus tarsi implant. ... controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when indicated, to ...
(Date:4/30/2016)... ... ... a challenge for all of us, but there are things we can do to improve the ... is showing more and more that there are simple, yet important steps that can be taken ... priorities Dr. Kohli’s recommends for her patients include;, , exercise , ...
(Date:4/30/2016)... ... , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of Indianapolis to ... the care of Maximized Living doctors at the London Olympics in 2012, U.S. wrestlers ... sending the largest contingent of elite chiropractors to Rio to support and care for ...
(Date:4/29/2016)... FL (PRWEB) , ... April 30, 2016 , ... ... and engineer of patented products, announces the Pick Up Springboard, an automotive invention ... and Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Tie-up with Government ... to save newborns   Fortis La ... newborns in collaboration with Breast Milk Foundation (BMF), a non-profit ... Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre ... for infants and should be available to babies deprived of ...
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
(Date:4/26/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) is ... , Pharm D., to Vice President of Education and ... Hagerman will continue to lead and oversee Diplomat University, ... education and training to Diplomat employees and external professionals ... University also houses the quality assurance department, which focuses ...
Breaking Medicine Technology: